Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Sermorelin vs Synthetic HGH: Clinical Comparison

Mechanism of Action Binds to GHRH receptors on pituitary somatotrophs, stimulating endogenous GH release Directly replaces endogenous GH with exogenous bioidentical hormone Sermorelin preserves pituitary function; HGH suppresses it GH Release Pattern Pulsatile

This comparison does not assign a generated winner or score.

  • Mechanism of Action
  • Binds to GHRH receptors on pituitary somatotrophs, stimulating endogenous GH release
  • Directly replaces endogenous GH with exogenous bioidentical hormone
  • Sermorelin preserves pituitary function; HGH suppresses it
  • GH Release Pattern
  • Pulsatile, mirroring natural circadian rhythm (peak during sleep)
  • Continuous elevation with no pulsatility
  • Pulsatile release maintains feedback regulation; continuous elevation increases side effect risk
  • IGF-1 Response
  • Gradual rise over 4–8 weeks, typically 30–40% increase from baseline
  • Rapid rise within 2–4 weeks, often 50–70% increase
  • Sermorelin produces physiological IGF-1 levels; HGH can push supraphysiological
  • Impact on Endogenous GH
  • Preserves and potentially restores pituitary GH secretion
  • Suppresses endogenous GH production by 70–90% within 8–12 weeks
  • Sermorelin avoids dependence; HGH creates it
  • Side Effect Profile
  • Mild. Injection site reactions, transient flushing (5–8% incidence)
  • Moderate to significant. Joint pain, edema, carpal tunnel syndrome (18–25% incidence)
  • Sermorelin better tolerated long-term
  • Regulatory Status
  • Not a controlled substance; off-label use permitted
  • Schedule III controlled substance; prescribing outside FDA indications carries legal risk
  • Sermorelin more accessible for anti-aging and wellness protocols
  • Cost per Month
  • $150–$350 (compounded, research-grade)
  • $800–$1,500 (brand-name pharmaceutical)
  • Sermorelin 60–75% less expensive
  • Professional Assessment
  • Sermorelin is the mechanistically cleaner option for patients who want GH benefits without shutting down endogenous production. It's the first-line choice for body composition, metabolic health, and longevity protocols where preserving natural hormone signaling matters more than maximizing absolute GH levels.
  • Synthetic HGH remains necessary for severe GH deficiency (pediatric growth failure, documented pituitary disease) where endogenous production is absent. But for off-label wellness use, the suppression risk and cost make it a less practical long-term option.
More references

Related material